Spots Global Cancer Trial Database for Comparison of Brivanib and Best Supportive Care (BSC) With Placebo and BSC for Treatment of Liver Cancer in Asian Patients Who Have Failed Sorafenib Treatment
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Comparison of Brivanib and Best Supportive Care (BSC) With Placebo and BSC for Treatment of Liver Cancer in Asian Patients Who Have Failed Sorafenib Treatment
Official Title: A Randomized, Double-blind, Multi-center Phase III Study of Brivanib Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Asian Subjects With Advanced Hepatocellular Carcinoma (HCC) Who Have Failed or Are Intolerant to Sorafenib
Study ID: NCT01108705
Conditions
Study Description
Brief Summary: The purpose of this study is to determine whether brivanib is an effective treatment for liver cancer in Asian patients who have failed or could not tolerate sorafenib therapy.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Local Institution, Hefei, Anhui, China
Local Institution, Beijing, Beijing, China
Local Institution, Beijing, Beijing, China
Local Institution, Beijing, Beijing, China
Local Institution, Chongqing, Chongqing, China
Local Institution, Fu Zhou, Fujian, China
Local Institution, Fuzhou, Fujian, China
Local Institution, Guangzhou, Guangdong, China
Local Institution, Guangzhou, Guangdong, China
Local Institution, Guanzhou, Guangdong, China
Local Institution, Ha Erbin, Heilongjiang, China
Local Institution, Hankou, Hubei, China
Local Institution, Wuhan, Hubei, China
Local Institution, Nanjing, Jiangsu, China
Local Institution, Nanjing, Jiangsu, China
Local Institution, Suzhou, Jiangsu, China
Local Institution, Chang Chun, Jilin, China
Local Institution, Changchun, Jilin, China
Local Institution, Shenyang, Liaoning, China
Local Institution, Shanghai, Shanghai, China
Local Institution, Shanghai, Shanghai, China
Local Institution, Chengdu, Sichuan, China
Local Institution, Tianjing, Tianjin, China
Local Institution, Hangzhou, Zhejiang, China
Local Institution, Xi An, , China
Local Institution, Xi'an, , China
Local Institution, Gyeonggi-do, , Korea, Republic of
Local Institution, Seoul, , Korea, Republic of
Local Institution, Singapore, , Singapore
Local Institution, Kaohsiung County, , Taiwan
Local Institution, Taipei, , Taiwan
Local Institution, Taoyuan, , Taiwan
Contact Details
Name: Bristol-Myers Squibb
Affiliation: Bristol-Myers Squibb
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
